5,000 volunteers tracked to see if chikungunya vaccine is safe

NCT ID NCT07254702

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 22, 2026 · Updated 4 times

Summary

This observational study will follow 5,000 people who received the VLA1553 chikungunya vaccine as part of a pilot vaccination program. Researchers will monitor for specific safety concerns like chikungunya-like reactions, heart problems, and arthritis over 60 days. The goal is to estimate how often these side effects occur and measure any increased risk linked to the vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VLA1553 live-attenuated chikungunya vaccine
What this could lead to: If this study confirms the vaccine is safe, it could support wider use of VLA1553 to prevent chikungunya virus infection.
What could go wrong: This is an observational study, not a controlled trial, so it can't prove cause and effect. Rare side effects may still be missed even with 5,000 participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chikungunya prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS INFECTION

Contacts and locations

Locations

Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus

Laranjeiras, Sergipe, 49060-025, Brazil
Fundação Faculdade Regional De Medicina De São José Do Rio Preto

São Pedro, São Paulo, 15090-000, Brazil
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras

Belo Horizonte, Minas Gerais, 31270-901, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.